RT Journal Article
SR Electronic
T1 Histopathology of Third Trimester Placenta from SARS-CoV-2-Positive Women
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.11.20173005
DO 10.1101/2020.08.11.20173005
A1 He, Mai
A1 Skaria, Priya
A1 Kreutz, Kasey
A1 Chen, Ling
A1 Hagemann, Ian
A1 Carter, Ebony B.
A1 Mysorekar, Indira U.
A1 Nelson, D Michael
A1 Pfeifer, John
A1 Dehner, Louis P.
YR 2020
UL http://medrxiv.org/content/early/2020/08/12/2020.08.11.20173005.abstract
AB This study aims to investigate whether maternal SARS-CoV-2 status affect placental pathology.Methods A retrospective case-control study was conducted by reviewing charts and slides of placentas between April 1 to July 24, 2020. Clinical history of “COVID-19” were searched in Pathology Database (CoPath). Controls were matched with SARS-CoV-2-negative women with singleton deliveries in the 3rd-trimester. Individual and group, pathological features were extracted from placental pathology reports.Results Twenty-one 3rd-trimester, placentas from SARS-CoV-2-positive women were identified and compared to 20 placentas from SARS-CoV-2-negative women. There were no significant differences in individual or group gross or microscopic pathological features between the groups. Within the SARS-CoV-2+ group, there are no differences between symptomatic and asymptomatic women.Conclusion Placentas from SARS-CoV-2-positive women do not demonstrate a specific pathological pattern. Pregnancy complicated with COVID-19 during the 3rd trimester does not have a demonstrable effect on placental structure and pathology.Competing Interest StatementAll authors disclose no conflicts of interest, except that IUM serves on the Scientific Advisory Board of Luca Biologics.Funding StatementThis study was supported by the departmental faculty development to Dr. Mai He from the Department of Pathology & Immunology, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USAAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institution Review Board (IRB) approval: IRB ID# 201902092 was approved by the Office of Institution Review Board, Washington University in St. Louis. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot available